Talquetamab Clinical Trials (2026): 36 Studies for Multiple Myeloma & Relapsed or Refractory Multiple Myeloma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
36 Talquetamab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 13 indications (including Multiple Myeloma & Relapsed or Refractory Multiple Myeloma) and 7,100 total planned enrollment. 4 Phase 3 Talquetamab trials and 17 Phase 2, 1 Phase 4 are listed. 21 Talquetamab clinical trials are actively recruiting at 125 U.S. sites across 35 states. Most recent activity: NCT06855121 (Dec 2037).
Where to Participate: All Talquetamab Trial Sites in the U.S. (125 sites across 35 states)
Every actively recruiting Talquetamabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | University of Alabama Birmingham | Birmingham35294 | NCT04634552 | Map |
| AZ | Banner MD Anderson Cancer Center | Gilbert85234 | NCT05552222 | Map |
| AZ | Arizona Oncology Associates | Tucson85711 | NCT05972135 | Map |
| AZ | University of Arizona Cancer Center | Tucson85719 | NCT05552222 | Map |
| AR | University of Arkansas for Medical Sciences | Little Rock72205 | NCT04634552 | Map |
| CA | UCSF Fresno | Clovis93611 | NCT05552222 | Map |
| CA | City of Hope Duarte | Duarte91010 | NCT05552222 | Map |
| CA | City of Hope Medical Center | Duarte91010 | NCT06572605 | Map |
| CA | City of Hope Orange County Lennar Foundation Cancer Center | Irvine92618 | NCT05552222 | Map |
| CA | Cancer and Blood Specialty Clinic | Los Alamitos90720 | NCT05552222 | Map |
| CA | Valkyrie Clinical Trials | Los Angeles90067 | NCT05552222 | Map |
| CA | Stanford University | Palo Alto94304 | NCT06461988 | Map |
| CA | University of Calfornia, San Francisco | San Francisco94143 | NCT06348108 | Map |
| CA | University of California San Francisco | San Francisco94143 | NCT06500884 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT05972135 | Map |
| CO | Colorado Blood Cancer Institute | Denver80218 | NCT06500884 | Map |
| CO | Rocky Mountain Cancer Center | Denver80218 | NCT05972135 | Map |
| CT | University of Connecticut | Farmington06030 | NCT05552222 | Map |
| CT | Yale New Haven Hospital | New Haven06510 | NCT05552222 | Map |
| CT | Yale University | New Haven06519 | NCT06993675 | Map |
| CT | Yale University School Of Medicine | New Haven06510 | NCT06500884 | Map |
| DE | ChristianaCare Helen F Graham Cancer Center and Research Institute | Newark19713 | NCT05552222 | Map |
| DE | Medical Oncology Hematology Consultants | Newark19713 | NCT05972135 | Map |
| DE | Medical Oncology Hematology Consultants, PA | Newark19713 | NCT06208150 | Map |
| FL | Memorial Healthcare System | Hollywood33021 | NCT05552222 | Map |
| FL | Memorial Healthcare System | Hollywood33021 | NCT04634552 | Map |
| FL | University of Miami | Miami33136 | NCT06100237 | Map |
| FL | AdventHealth Medical Group Blood & Marrow Transplant at Orlando | Orlando32804 | NCT05552222 | Map |
| FL | Cleveland Clinic Florida | Weston33331 | NCT05552222 | Map |
| GA | Emory University Winship Cancer Institute | Atlanta30322 | NCT04634552 | Map |
| GA | City of Hope Cancer Center | Newnan30265 | NCT05552222 | Map |
| GA | City of Hope Cancer Center | Newnan30265 | NCT06208150 | Map |
| IL | University of Chicago | Chicago60637 | NCT04634552 | Map |
| IL | University Of Illinois Medical Center | Chicago60612 | NCT05552222 | Map |
| IL | Loyola University Medical Center | Maywood60153 | NCT05552222 | Map |
| IA | University of Iowa Health Care | Waukee50263 | NCT05552222 | Map |
| KY | Norton Cancer Institute | Louisville40207 | NCT05552222 | Map |
| KY | Norton Cancer Institute | Louisville40207 | NCT04634552 | Map |
| LA | Our Lady of the Lake Hospital | Baton Rouge70808 | NCT06208150 | Map |
| LA | LSUHSC Shreveport Feist-Weiller Cancer Center | Shreveport71103 | NCT05552222 | Map |
| MD | Johns Hopkins University School of Medicine JHUSOM | Baltimore21231 | NCT05552222 | Map |
| MD | University of Maryland School of Medicine | Baltimore21201 | NCT06208150 | Map |
| MD | Center for Cancer and Blood Disorders | Bethesda20817 | NCT05552222 | Map |
| MD | Maryland Oncology Hematology | Columbia21044 | NCT05972135 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT07032714 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT05552222 | Map |
| MI | University of Michigan Health System | Ann Arbor48109 | NCT04634552 | Map |
| MI | Henry Ford Cancer - Detroit Brigitte Harris Cancer Pavilion | Detroit48202 | NCT05552222 | Map |
| MI | Henry Ford Cancer Institute | Detroit48202 | NCT06208150 | Map |
| MI | Cancer And Hematology Centers of Western Michigan PC | Grand Rapids49503 | NCT05552222 | Map |
| MI | Henry Ford Providence Novi Hospital | Novi48374 | NCT05552222 | Map |
| MI | Henry Ford Providence Southfield CK Potluri Cancer Center | Southfield48075 | NCT05552222 | Map |
| MN | Minnesota Oncology Hematology | Minneapolis55404 | NCT05972135 | Map |
| MO | MidAmerica Cancer Care | Kansas City64132 | NCT05552222 | Map |
| MO | Washington University School Of Medicine | St Louis63110 | NCT04634552 | Map |
| NE | Nebraska Cancer Specialists | Omaha68130 | NCT05552222 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT05552222 | Map |
| NH | Dartmouth Hitchcock Medical Center | Lebanon03756 | NCT05552222 | Map |
| NJ | Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) | Basking Ridge07920 | NCT06066346 | Map |
| NJ | Astera Cancer Care | East Brunswick08816 | NCT05552222 | Map |
| NJ | Memorial Sloan Kettering Monmouth (Limited Protocol Activities) | Middletown07748 | NCT06066346 | Map |
| NJ | Memorial Sloan Kettering Bergen (Limited Protocol Activities) | Montvale07645 | NCT06066346 | Map |
| NM | Christus St. Vincent Regional Cancer Center | Santa Fe87505 | NCT05552222 | Map |
| NY | Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) | Commack11725 | NCT06066346 | Map |
| NY | Hematology-Oncology Associates of CNY | East Syracuse13057 | NCT05552222 | Map |
| NY | Memorial Sloan Kettering Westchester (Limited Protocol Activities) | Harrison10604 | NCT06066346 | Map |
| NY | Northwell Health Cancer Institute | Lake Success11042 | NCT05552222 | Map |
| NY | NYU Langone Hospital Long Island | Mineola11500 | NCT05552222 | Map |
| NY | Icahn School of Medicine at Mount Sinai | New York10029 | NCT06827860 | Map |
| NY | Icahn School of Medicine at Mt. Sinai | New York10029 | NCT06500884 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05552222 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT06066346 | Map |
| NY | Mount Sinai Medical Center | New York10023 | NCT04634552 | Map |
| NY | Perlmutter Cancer Center at NYU Langone Health | New York10016 | NCT05552222 | Map |
| NY | Weill Cornell Medical College | New York10065 | NCT05552222 | Map |
| NY | Weill Cornell Medical College | New York10065 | NCT06208150 | Map |
| NY | University of Rochester Medical Center | Rochester14642 | NCT04634552 | Map |
| NY | University of Rochester Medical Center | Rochester14642 | NCT06500884 | Map |
| NY | SUNY Upstate Medical University | Syracuse13210 | NCT06208150 | Map |
| NY | Memorial Sloan Kettering Nassau (Limited Protocol Activities) | Uniondale11553 | NCT06066346 | Map |
| NC | Levine Cancer Institute | Charlotte28204 | NCT05552222 | Map |
| NC | Novant Health | Charlotte28204 | NCT05552222 | Map |
| NC | Duke University Medical Center | Durham27705 | NCT06500884 | Map |
| NC | Durham VAMC | Durham27705 | NCT05552222 | Map |
| NC | Virginia Oncology Associates | Elizabeth City27909 | NCT05972135 | Map |
| NC | Novant Health Zimmer Cancer Institute | Wilmington28401 | NCT05552222 | Map |
| NC | Atrium Health Wake Forest Baptist Comprehensive Cancer Center | Winston-Salem27157 | NCT05552222 | Map |
| NC | Novant Health Forsyth Medical Center | Winston-Salem27103 | NCT05552222 | Map |
| OH | Oncology Hematology Care | Cincinnati45236 | NCT05552222 | Map |
| OH | Oncology Hematology Care | Cincinnati45242 | NCT05972135 | Map |
| OH | The Christ Hospital Cancer Center | Cincinnati45219 | NCT05552222 | Map |
| OH | University of Cincinnati | Cincinnati45267 | NCT05552222 | Map |
| OH | Cleveland Clinic Main Campus | Cleveland44195 | NCT05552222 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT05552222 | Map |
| OH | University Hospitals Cleveland Medical Center | Cleveland44106 | NCT06500884 | Map |
| OH | OhioHealth | Columbus43214 | NCT05552222 | Map |
| OH | The Ohio State University- James Cancer Hospital | Columbus43210 | NCT05552222 | Map |
| OR | Oncology Associates of Oregon | Eugene97401 | NCT05972135 | Map |
| PA | Penn State Milton S Hershey Medical Ctr | Hershey17033 | NCT05552222 | Map |
| PA | Allegheny Health Network | Pittsburgh15224 | NCT05552222 | Map |
| RI | Rhode Island Hospital | Providence02903 | NCT05552222 | Map |
| SC | Medical University of South Carolina | Charleston29425-8900 | NCT06208150 | Map |
| SC | MUSC-Hollings Cancer Center | Charleston29425 | NCT05552222 | Map |
| TN | Henry-Joyce Cancer Clinic | Nashville37232 | NCT05552222 | Map |
| TN | TriStar Bone Marrow Transplant | Nashville37203 | NCT05972135 | Map |
| TN | Vanderbilt- Ingram Cancer Center | Nashville37232 | NCT05972135 | Map |
| TX | Texas Oncology | Austin78705 | NCT05972135 | Map |
| TX | University of Texas Southwestern Medical Center | Dallas75235 | NCT05552222 | Map |
| TX | Houston Methodist Hospital | Houston77030 | NCT05552222 | Map |
| TX | Joe Arrington Cancer Research Treatment Center | Lubbock79410 | NCT05552222 | Map |
| TX | Texas Oncology - San Antonio | San Antonio78240 | NCT05972135 | Map |
| TX | Texas Oncology - Northeast Texas | Tyler75702 | NCT05972135 | Map |
| UT | Huntsman Cancer Institute | Salt Lake City84112 | NCT05552222 | Map |
| UT | Utah Cancer Specialists | Salt Lake City84106 | NCT05552222 | Map |
| VA | Virginia Cancer Specialists | Fairfax22031 | NCT05972135 | Map |
| VA | Alexander T. Augusta Military Medical Center | Fort Belvoir22060 | NCT05552222 | Map |
| VA | Virginia Oncology Associates Brock Cancer Center | Norfolk23502 | NCT05552222 | Map |
| VA | Richmond VA Medical Center | Richmond23249 | NCT05552222 | Map |
| VA | Virginia Commonwealth University - Massey Cancer Center | Richmond23298 | NCT06500884 | Map |
| VA | Virginia Commonwealth University Medical Center | Richmond23298 | NCT05552222 | Map |
| VA | Blue Ridge Cancer Center | Roanoke24014 | NCT05972135 | Map |
| WA | University of Washington | Seattle98109 | NCT06500884 | Map |
| WA | NorthWest Medical Specialties, PLLC | Tacoma98405 | NCT05552222 | Map |
| WI | Gundersen Health System | La Crosse54601 | NCT06208150 | Map |
| WI | Froedtert & the Medical College of Wisconsin | Milwaukee53226 | NCT07093554 | Map |
Talquetamab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | withdrawn | not yet recruiting | no longer available | approved for marketing | Total |
|---|---|---|---|---|---|---|---|---|
| P1 | 3 | 4 | 1 | 8 | ||||
| P1/P2 | 1 | 1 | 2 | |||||
| P2 | 11 | 4 | 1 | 1 | 17 | |||
| P3 | 2 | 1 | 1 | 4 | ||||
| P4 | 1 | 1 | ||||||
| N/A | 1 | 1 | 1 | 1 | 4 |
Recruiting Talquetamab clinical trials (21)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT06855121 | NIMMSThe Norwegian Immunotherapy in Multiple Myeloma Study | — | Myeloma Multiple | 400 | Jan 2025 |
| NCT07474961 | BLOOD-doseBLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. | P4 | Waldenstrom Macroglobulinaemia | 400 | Mar 2027 |
| NCT07107529 | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | P2 | Multiple Myeloma (MM) | 150 | Dec 2025 |
| NCT05552222 | MajesTEC-7A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | P3 | Multiple Myeloma | 1,590 | Oct 2022 |
| NCT07029776 | MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma | P2 | Multiple Myeloma (MM) | 50 | Jul 2026 |
| NCT06500884 | TalismanA Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events | P2 | Multiple Myeloma | 210 | Aug 2024 |
| NCT06572605 | External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease | P1/P2 | Extramedullary Disease in Multiple Myeloma | 20 | Aug 2025 |
| NCT06100237 | REVIVETeclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) | P2 | Multiple Myeloma | 50 | Dec 2023 |
| NCT05695508 | HD10/DSMMXXGMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 | P2 | Multiple Myeloma | 160 | Dec 2022 |
| NCT06993675 | ROTATEEngaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) | P2 | Multiple Myeloma | 50 | Aug 2025 |
| NCT06348108 | Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | P1 | Multiple Myeloma | 32 | Jul 2025 |
| NCT04634552 | MonumenTAL-1A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | P2 | Hematological Malignancies | 510 | Feb 2021 |
| NCT06208150 | MonumenTAL-6A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | P3 | Multiple Myeloma | 795 | Jan 2024 |
| NCT06505369 | TALTECBispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients | P2 | Multiple Myeloma | 50 | Jun 2024 |
| NCT07032714 | MAGENTAMezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma | P1 | Relapsed Refractory Multiple Myeloma (RRMM) | 25 | Dec 2025 |
| NCT06827860 | Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse | P2 | Multiple Myeloma in Relapse | 23 | Nov 2025 |
| NCT07093554 | Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma | P1 | Relapse Multiple Myeloma | 31 | Dec 2025 |
| NCT05972135 | Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | P2 | Multiple Myeloma | 100 | Oct 2023 |
| NCT06066346 | A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy | P2 | Multiple Myeloma | 17 | Sep 2023 |
| NCT07499323 | Talquetamab in Patients With Refractory Generalized Myasthenia Gravis | N/A | Myasthenia Gravis (MG) | 2 | Mar 2026 |
| NCT06461988 | Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma | P2 | Multiple Myeloma | 20 | Jun 2025 |
Talquetamab clinical trials by indication
Multiple Myeloma (20)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05552222 | MajesTEC-7 | P3 | recruiting | A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma |
| NCT06577025 | aMMbition | P2 | active not recruiting | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma |
| NCT06353022 | IFm2022-01 | P2 | active not recruiting | Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma |
| NCT06500884 | Talisman | P2 | recruiting | A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events |
| NCT06100237 | REVIVE | P2 | recruiting | Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) |
| NCT05695508 | HD10/DSMMXX | P2 | recruiting | GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 |
| NCT06993675 | ROTATE | P2 | recruiting | Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) |
| NCT06348108 | — | P1 | recruiting | Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma |
| + 12 more, see All trials below. | ||||
Multiple Myeloma (MM) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07107529 | — | P2 | recruiting | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. |
| NCT07029776 | — | P2 | not yet recruiting | MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma |
Relapsed/ Refractory Multiple Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05338775 | TRIMM-3 | P1 | active not recruiting | A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma |
| NCT05461209 | MonumenTAL-5 | P3 | withdrawn | A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma |
Hematological Malignancies (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04634552 | MonumenTAL-1 | P2 | recruiting | A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma |
| NCT03399799 | MonumenTAL-1 | P1 | active not recruiting | Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma |
Relapsed or Refractory Multiple Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05757973 | — | N/A | approved for marketing | Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma |
| NCT05503550 | — | N/A | no longer available | Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma |
Waldenstrom Macroglobulinaemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07474961 | BLOOD-dose | P4 | not yet recruiting | BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. |
Myasthenia Gravis (MG) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07499323 | — | N/A | not yet recruiting | Talquetamab in Patients With Refractory Generalized Myasthenia Gravis |
Relapsed Refractory Multiple Myeloma (RRMM) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07032714 | MAGENTA | P1 | recruiting | Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma |
Relapse Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07093554 | — | P1 | recruiting | Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma |
Multiple Myeloma in Relapse (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06827860 | — | P2 | recruiting | Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse |
Extramedullary Disease in Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06572605 | — | P1/P2 | recruiting | External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease |
Myeloma Multiple (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06855121 | NIMMS | N/A | recruiting | The Norwegian Immunotherapy in Multiple Myeloma Study |
High-Risk de Novo Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05849610 | GEM-TECTAL | P2 | active not recruiting | Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma |
Talquetamab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| BLOOD-dose | NCT07474961 | P4 | not yet recruiting | Waldenstrom Macroglobulinaemia | 400 | — |
| MajesTEC-7 | NCT05552222 | P3 | recruiting | Multiple Myeloma | 1,590 | — |
| MonumenTAL-6 | NCT06208150 | P3 | recruiting | Multiple Myeloma | 795 | — |
| MonumenTAL-3 | NCT05455320 | P3 | active not recruiting | Multiple Myeloma | 864 | — |
| MonumenTAL-5 | NCT05461209 | P3 | withdrawn | Relapsed/ Refractory Multiple Myeloma | 0 | — |
| aMMbition | NCT06577025 | P2 | active not recruiting | Multiple Myeloma | 43 | — |
| IFm2022-01 | NCT06353022 | P2 | active not recruiting | Multiple Myeloma | 103 | — |
| Talisman | NCT06500884 | P2 | recruiting | Multiple Myeloma | 210 | — |
| REVIVE | NCT06100237 | P2 | recruiting | Multiple Myeloma | 50 | — |
| HD10/DSMMXX | NCT05695508 | P2 | recruiting | Multiple Myeloma | 160 | — |
| ROTATE | NCT06993675 | P2 | recruiting | Multiple Myeloma | 50 | — |
| GEM-TECTAL | NCT05849610 | P2 | active not recruiting | High-Risk de Novo Multiple Myeloma | 30 | — |
| MonumenTAL-1 | NCT04634552 | P2 | recruiting | Hematological Malignancies | 510 | — |
| TALTEC | NCT06505369 | P2 | recruiting | Multiple Myeloma | 50 | — |
| MonumenTAL-8 | NCT06550895 | P2 | active not recruiting | Multiple Myeloma | 11 | — |
| KarMMa-2 | NCT03601078 | P2 | completed | Multiple Myeloma | 312 | — |
Terminated and withdrawn Talquetamab trials (1)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05461209withdrawnA Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma
All Talquetamab trials (36)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT06855121 | NIMMS | The Norwegian Immunotherapy in Multiple Myeloma Study | — | recruiting | 400 | St. Olavs Hospital | Jan 2025 |
| NCT07474961 | BLOOD-dose | BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. | P4 | not yet recruiting | 400 | Anne Louise Tølbøll Sørensen | Mar 2027 |
| NCT07107529 | Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. | P2 | recruiting | 150 | European Myeloma Network B.V. | Dec 2025 | |
| NCT05552222 | MajesTEC-7 | A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | P3 | recruiting | 1,590 | Janssen Research & Development, LLC | Oct 2022 |
| NCT07029776 | MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma | P2 | not yet recruiting | 50 | University of Arkansas | Jul 2026 | |
| NCT06577025 | aMMbition | A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma | P2 | active not recruiting | 43 | Janssen Research & Development, LLC | Aug 2024 |
| NCT06353022 | IFm2022-01 | Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma | P2 | active not recruiting | 103 | Nantes University Hospital | Jun 2024 |
| NCT06500884 | Talisman | A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events | P2 | recruiting | 210 | Janssen Research & Development, LLC | Aug 2024 |
| NCT06572605 | External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease | P1/P2 | recruiting | 20 | City of Hope Medical Center | Aug 2025 | |
| NCT06100237 | REVIVE | Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) | P2 | recruiting | 50 | Carl Ola Landgren, MD, PhD | Dec 2023 |
| NCT05695508 | HD10/DSMMXX | GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 | P2 | recruiting | 160 | University of Heidelberg Medical Center | Dec 2022 |
| NCT06993675 | ROTATE | Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) | P2 | recruiting | 50 | Noffar Bar | Aug 2025 |
| NCT06348108 | Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma | P1 | recruiting | 32 | Alfred Chung, MD | Jul 2025 | |
| NCT05849610 | GEM-TECTAL | Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma | P2 | active not recruiting | 30 | PETHEMA Foundation | Sep 2023 |
| NCT04634552 | MonumenTAL-1 | A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | P2 | recruiting | 510 | Janssen Research & Development, LLC | Feb 2021 |
| NCT06208150 | MonumenTAL-6 | A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | P3 | recruiting | 795 | Janssen Research & Development, LLC | Jan 2024 |
| NCT06505369 | TALTEC | Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients | P2 | recruiting | 50 | North Estonia Medical Centre | Jun 2024 |
| NCT07032714 | MAGENTA | Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma | P1 | recruiting | 25 | Massachusetts General Hospital | Dec 2025 |
| NCT05455320 | MonumenTAL-3 | A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment | P3 | active not recruiting | 864 | Janssen Research & Development, LLC | Oct 2022 |
| NCT06827860 | Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse | P2 | recruiting | 23 | Larysa Sanchez | Nov 2025 | |
| NCT07093554 | Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma | P1 | recruiting | 31 | Medical College of Wisconsin | Dec 2025 | |
| NCT05972135 | Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | P2 | recruiting | 100 | SCRI Development Innovations, LLC | Oct 2023 | |
| NCT06066346 | A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy | P2 | recruiting | 17 | Memorial Sloan Kettering Cancer Center | Sep 2023 | |
| NCT03399799 | MonumenTAL-1 | Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | P1 | active not recruiting | 279 | Janssen Research & Development, LLC | Dec 2017 |
| NCT05050097 | MonumenTAL-2 | A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma | P1 | active not recruiting | 166 | Janssen Research & Development, LLC | Sep 2021 |
| NCT06550895 | MonumenTAL-8 | A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma | P2 | active not recruiting | 11 | Janssen Research & Development, LLC | Sep 2024 |
| NCT05338775 | TRIMM-3 | A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma | P1 | active not recruiting | 74 | Janssen Research & Development, LLC | May 2022 |
| NCT04108195 | A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma | P1 | active not recruiting | 290 | Janssen Research & Development, LLC | Feb 2020 | |
| NCT07499323 | Talquetamab in Patients With Refractory Generalized Myasthenia Gravis | N/A | not yet recruiting | 2 | First Affiliated Hospital of Chongqing Medical University | Mar 2026 | |
| NCT04586426 | RedirecTT-1 | A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma | P1/P2 | active not recruiting | 228 | Janssen Research & Development, LLC | Dec 2020 |
| NCT06461988 | Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma | P2 | recruiting | 20 | Stanford University | Jun 2025 | |
| NCT03601078 | KarMMa-2 | An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma | P2 | completed | 312 | Celgene | Dec 2018 |
| NCT04773522 | A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma | P1 | completed | 15 | Janssen Pharmaceutical K.K. | May 2021 | |
| NCT05461209 | MonumenTAL-5 | A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma | P3 | withdrawn | 0 | Janssen Research & Development, LLC | Oct 2022 |
| NCT05757973 | Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma | — | approved for marketing | 0 | Janssen Research & Development, LLC | — | |
| NCT05503550 | Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma | — | no longer available | 0 | Janssen Research & Development, LLC | — |
Talquetamab clinical trials: frequently asked questions
- How many Talquetamab clinical trials are there?
- 36 Talquetamab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 18 are actively recruiting participants. 2 are marked completed.
- Are Talquetamab clinical trials recruiting in 2026?
- Yes — 18 Talquetamab trials are actively recruiting in 2026, with 125 U.S. sites across 35 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Talquetamab being studied for?
- Talquetamab is being studied for Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Multiple Myeloma (MM), Hematological Malignancies, Relapsed/ Refractory Multiple Myeloma and 13 more. The trials are grouped by indication on this page.
- What phase is Talquetamab in?
- Talquetamab clinical trials span 1 Phase 4, 4 Phase 3, 17 Phase 2, 8 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Talquetamab clinical trials?
- The lead sponsor across the most Talquetamab trials is Janssen Research & Development, LLC, with 21 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Talquetamabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: